Simvastatin

Journal of Drug Evaluation: Cardiovascular Medicine

Volumn 1, Issue 2, 2002, Pages 53-88

  Thompson, Gilbert R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINOTRANSFERASE; ASCORBIC ACID; ATORVASTATIN; BETA CAROTENE; BEZAFIBRATE; COLESTYRAMINE; COMPACTIN; CYCLOSPORIN; DILTIAZEM; ENALAPRIL; ERYTHROMYCIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; MITOTANE; NELFINAVIR; NICOTINIC ACID; PHENYTOIN; PHYTOSTEROL; PLACEBO; PRAVASTATIN; RIFAMPICIN; SELENIUM; SIMVASTATIN; STANOL ESTER; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BILE; CATARACT; CHEMICAL MODIFICATION; CHOLESTEROL SYNTHESIS; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; ENDOCRINE FUNCTION; EXPERIMENTAL ANIMAL; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FIRST PASS EFFECT; FLATULENCE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEADACHE; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; IN VITRO STUDY; LIPOPROTEIN METABOLISM; MYOPATHY; MYOSITIS; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; TERATOGENICITY; THROMBOCYTE;

EID: 0038515037     PISSN: 14723514     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (238)

1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-82
2. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976;29:1346-8
3. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Letts 1976;72:323-6
4. Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci USA 1973;70:2804-8
5. Kaneko I, Hazama-Shimada Y, Endo A. Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Eur J Biochem 1978;87:313-21
6. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980;35:259-66
7. Mabuchi H, Haba T, Tatami R, et al. Effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med 1981;305:478-82
8. Mabuchi H, Sakai T, Sakai Y, et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N Engl J Med 1983;308:609-13
9. Rudney H, Stewart PR, Majerus PW, et al. The biosynthesis of beta-hydroxy-beta-methylglutaryl coenzyme A in yeast. V. The role of acyl carrier protein. J Biol Chem 1966;241:1226-8
10. Alberts AW, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980;77:3957-61
11. Endo A. Monocolin K. A new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979;32:852-4
12. Tobert JA, Hitzenberger G, Kukovetz WR, et al. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis 1982;41:61-5
13. Tobert JA, Bell GD, Birtwell J, et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, in healthy volunteers. J Clin Invest 1982;69:913-19
14. Illingworth DR, Corbin D. The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia. Proc Natl Acad Sci USA 1985;82:6291-4
15. Bilheimer DW, Grundy SM, Brown MS, et al. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983;80:4124-8
16. Hoffman WF, Alberts AW, Anderson PS, et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J Med Chem 1986;29:849-52
17. Parfitt K, ed. Martindale: the Complete Drug Reference, 32nd edition. London: Pharmaceutical Press, 1999
18. Dollery C, ed. Therapeutic Drugs, 2nd edition. Edinburgh: Churchill Livingstone, 1999:S37-S42
19. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988;62:10J-15J
20. Serajuddin AT, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 1991;80:830-4
21. Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci Am 1984;251:52-60
22. Todd PA, Goa KL. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990;40:583-607
23. Alberts AW. HMG CoA reductase inhibitors - the development. Athero Rev 1988;11:123-31
24. Germershausen JI, Hunt VM, Bostedor RG, et al. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Comm 1989;158:667-75
25. Koga T, Fukuda K, Shimada Y, et al. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. Eur J Biochem 1992;209:315-19
26. Hidaka Y, Eda T, Yonemoto M, et al. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992;95:87-94
27. Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996;119:203-13
28. Kempen HJM, Glatz JFC, Gevers Leuven JA, et al. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988;29:1149-55
29. Feillet C, Farnier M, Monnier LH, et al. Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia. Atherosclerosis 1995;118:251-8
30. Naoumova RP, Dunn S, Rallidis L, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 1997;38:1496-500
31. Bergstrom JD, Bostedor RG, Rew DJ, et al. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase:a comparison of atorvastatin and simvastatin. Biochim Biophys Acta 1998;1389:213-21
32. Pfohl M, Naoumova RP, Kim K-D, et al. Use of cholesterol precursors to assess changes in cholesterol synthesis under non-steady-state conditions. Eur J Clin Invest 1998;28:491-6
33. Aguilar-Salinas CA, Barrett H, Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis 1998;141:203-7
34. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996;37:439-47
35. Watts GF, Naoumova RP, Kelly JM, et al. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997;273:E462-70
36. Malmendier CL, Lontie JF, Delcroix C, et al. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis 1989;80:101-9
37. Twickler TB, Dallinga-Thie GM, de Valk HW, et al. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:2422-7
38. Cabezas MC, De Bruin TWA, Kock LAW, et al. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism 1993;42:4497-503
39. Stein DT Devaraj S, Balis D, et al. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001;21:2026-31
40. Mölgaard J, Von Schenck H, Olsson AG. Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia. Eur Heart J 1988;9:541-51
41. Keech A, Collins R, MacMahon S, et al. Three year follow up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994;15:255-69
42. McPherson R. Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. Can J Clin Pharmacol 1999;6:85-90
43. Stein EA, Davidson MH, Dobs AS, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol 1998;82:311-16
44. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997;79:38-42
45. Haffner S, Orchard T, Stein E, et al. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 1995;18:261-7
46. Azzarito C, Boiardi L, Zini M, et al. Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients. Metabolism 1992;41:148-53
47. Mol MJ, Stalenhoef AF, Stuyt PM, et al. Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Clin Endocrinol 1989;31:679-89
48. Dobs AS, Schrott H, Davidson MH, et al. Effects of highdose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000;49:1234-8
49. Loria P, Bertolotti M, Cassinadri MT, et al. Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. Hepatology 1994;19:882-8
50. Naoumova RP, O'Neill FH, Dunn S, et al. Effect of inhibiting HMG-CoA reductase on 7α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Eur J Clin Invest 1999;29:404-12
51. Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988;8:1147-50
52. Wierzbicki AS, Lumb PJ, Chik G, et al. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract 1999;53:609-11
53. Stein EA, Lane MC, Villanueva J, et al. Effects of statins on plasma fibrinogen. Presented at the XIII International Symposium on Drugs Affecting Lipid Metabolism. Florence, Italy, 1998:84
54. Rosensen RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001;155:463-6
55. Mitropoulos KA, Armitage JM, Collins R, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acid. The Oxford Cholesterol Study Group. Eur Heart J 1997;18:235-41
56. Bröijersén A, Eriksson M, Leijd B, et al. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:273-8
57. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary endothelial cells. Life Sci 2000;67:863-76
58. Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-31
59. Jialal I, Stein D, Balis D. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5
60. Strandberg TE, Vanhanen H, Tikkanen MJ. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 2000;32:5579-83
61. Morschladt MF, de Maat MP, Westendorp RG, et al. C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy. Atherosclerosis 2001;157:491-4
62. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402
63. Sadeghi MM, Tiglio A, Sadigh K, et al. Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 2001;71:1262-8
64. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993;1165:335-8
65. Kleinveld HA, Demacker PN, De Haan AF, et al. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 1993;23:289-95
66. Tomas M, Senti M, Garcia-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000;20:2113-19
67. Carlucci G, Mazzeo P, Biordi L, et al. Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high-performance liquid chromatography with UV detection. J Pharm Biomed Anal 1992;10:693-7
68. Morris MJ, Gilbert JD, Hsieh JY, et al. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Biol Mass Spectrom 1993;22:1-8
69. Zhao JJ, Xie IH, Yang AY, et al. Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2000;35:1133-43
70. Gruer PJK, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999;84:811-15
71. Horsmans Y, Desager JP, van den Berge V, et al. Effects of simvastatin and pravastatin on 6-beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. Pharmacol Res 1993;28:243-8
72. Mol MJTM, Erkelens DW, Gevers Leuven JA, et al. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet 1986;2:936-9
73. Saito Y, Yoshida S, Nakaya N, et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991;11:816-26
74. Saheki A, Terasaki T, Tamai I, et al. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994;11:305-11
75. Schachter M. Statins, drug interactions and cytochrome P450. Br J Cardiol 2001;8:311-17
76. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83
77. Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 2000;68:384-90
78. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82
79. Mousa O, Brater DC, Sunblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000;67:267-74
80. Yeo KR, Yeo WW, Wallis EJ, et al. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br J Clin Pharmacol 1999;48:610-15
81. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001;45:3445-50
82. Kyrklund C, Backman JT, Kivisto KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000;68:592-7
83. Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 1999;75:359-60
84. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9
85. Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001;69:340-5
86. Gerson RJ, MacDonald JS, Alberts AW, et al. Animal safety and toxicology of simvastatin and related hydroxymethyl-glutaryl-coenzyme A reductase inhibitors. Am J Med 1989;87:4A-28S-38S
87. Nakahara K, Kuriyama M, Yoshidome H, et al. Experimental simvastatin-induced myopathy in rabbits. J Neurol Sci 1992;113:114-17
88. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991;257:1225-35
89. Minsker DH, MacDonald JS, Robertson RT, et al. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Teratology 1983;28:449-56
90. Thompson GR. A Handbook of Hyperlipidaemia. London: Current Science Ltd, 1994
91. Erkelens DW Baggen MGA, Van Doormaal JJ, et al. Clinical experience with simvastatin compared with cholestyramine. Drugs 1988;36 Suppl 3:87-92
92. Marais AD, Wood L, Firth JC, et al. Plasma exchange for homozygous familial hypercholesterolaemia: the Cape Town experience. Transfus Sci 1993;14:239-47
93. Raal FJ, Pilcher GJ, Illingworth DR, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 1997;135:249-56
94. Thompson GR, Packard CJ, Stone NJ. Goals of statin therapy: three viewpoints. Curr Atheroscler Reports 2002;4:26-33
95. Bredie SJ, de Bruin TW, Demacker PN, et al. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995;75:348-53
96. Kehely A, MacMahon M, Barbir M, et al. Combined bezafibrate and simvastatin treatment for mixed hyperlipidemia. Q J Med 1995;88:421-7
97. Darling GM, Johns JA, McCloud PI, et al. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601
98. Sbarouni E, Kyriakides ZS, Kremastinos DTh. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998;32:1244-50
99. Fak AS, Erenus M, Tezcan H, et al. Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on serum lipid levels in hypercholesterolaemic post-menopausal women. Eur Heart J 2000;21:190-7
100. Hulley S, Grady D, Bush T, et al for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13
101. The European Study Group. Efficacy and tolerability of sinavastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). Am J Cardiol 1992;70:1281-6
102. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993;71:1408-14
103. Stalenhoef AF, Lansberg PJ, Kroon AA, et al. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study. J Intern Med 1993;234:77-82
104. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7
105. Branchi A, Fiorenza AM, Rovellini A, et al. Lowering effects of four different statins on serum triglyceride level. Eur J Clin Pharmacol 1999;55:499-502
106. Branchi A, Fiorenza AM, Torri A, et al. Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia. Clin Ther 2001;23:851-7
107. Kastelein JJP, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1 levels. Am J Cardiol 2000;86:221-2
108. Illingworth DR, Crouse JR 3rd, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001;17:43-50
109. Simons LA, Simons J, McManus P, et al. Discontinuation rates for use of statins are high. Br Med J 2000;321:1084
110. Cobb MM, Teitelbaum HS, Breslow JL. Lovastatin efficacy in reducing low-density lipoprotein cholesterol levels on high- vs low-fat diets. JAMA 1991;265:997-1001
111. Chisholm A, Mann J, Sutherland W, et al. Dietary management of patients with familial hypercholesterolaemia treated with simvastatin. Q J Med 1992;85:825-31
112. Merck. Information Package DA-ZCR27(3). Merck
113. Pazzucconi F, Dorigotti F, Gianfranceschi G, et al. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis 1995;117:189-98
114. Thompson GR. Poor responders to statins: a potential target for stanol esters. Eur Heart J 1991;1 (suppl S):s114-17
115. Couture P, Brun LD, Szots F, et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998;18:1007-12
116. Miettinen TA, Strandberg TE, Gylling H, for the Finnish Investigators of the Scandinavian Simvastatin Survival Study Group. Non-cholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients. Relation to basal serum cholesterol. Arterioscler Thromb Vasc Biol 2000;20:1340-6
117. O'Neill FH, Patel DD, Knight BL, et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2001;21:832-7
118. Thompson GR, O'Neill F, Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 2002;23:200-6
119. Drmanac S, Heilbron DC, Pullinger CR, et al. Elevated baseline triglyceride levels modulate effects of HMG CoA reductase inhibitors on plasma lipoproteins. J Cardiovasc Pharmacol Ther 2001;6:47-56
120. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-15
121. Luscher TF, Tanner FC, Tschudi MR, et al. Endothelial dysfunction in coronary artery disease. Annu Rev Med 1993;44:395-418
122. Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82
123. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993;341:1496-500
124. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996;77:37-40
125. Alonso R, Mata P, De Andres R, et al. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis 2001;157:423-9
126. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31
127. Baller D, Notohamiprodjo G, Gleichmann U, et al. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5
128. De Divitiis M, Rubba P, Di Somma S, et al. Effects of short-tem reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia. Am J Cardiol 1996;78:763-8
129. Wilson SH, Simari RD, Best PJ, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:122-8
130. Cummings MH, Watts GF. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin Chem 1995;41:111-14
131. Ginsberg HN, Le NA, Short MP. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest 1987;80:1692-7
132. Iverson SA, Cairns DSR, Ward CP, et al. Asymptomatic cholesteryl ester storage disease in an adult controlled with simvastatin. Ann Clin Biochem 1997;34:433-6
133. Jira PE, Wevers RA, de Jong J, et al. Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome. J Lipid Res 2000;41:1339-46
134. Maher VMG, Trainer PJ, Scoppola A, et al. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia. Q J Med 1992;84:671-9
135. Siegel RD, Cupples A, Schaefer EJ, et al. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996;45:1267-72
136. Tikkanen MJ, Laakso M, Ilmonen M, et al. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabet Care 1998;21:477-81
137. Jeck T, Riesen WF, Keller U. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM. Diabet Med 1997;14:564-70
138. Sweany AE, Shapiro DR, Tate AC, et al. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group. Clin Ther 1995;17:186-203
139. Stein E, Plotkin D, Bays H, et al. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol 2000;86:406-11
140. Gavish D, Leibovitz E, Shapira I, et al. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000;247:563-9
141. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridemia. Heart 2001;85:544-8
142. Rabelink AJ, Hene RJ, Erkelens DW, et al. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988;2:1335-8
143. Nishikawa O, Mune M, Miyano M, et al. Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int 1999;71 (suppl):s219-21
144. Walker RJ, Sutherland WH, Walker HL, et al. Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrol Dial Transplant 1997;12:87-92
145. Malyszko J, Malyszko JS, Hryszko T, et al. Effects of longterm treatment with simvastatin on some hemostatic parameters in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 2001;21:373-7
146. Ichimaru N, Takahara S, Kokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001;158:417-23
147. Rayner BL, Byrne MJ, van Zyl Smit R. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 1996;46:219-24
148. Van Dijk MA, Kamper AM, van Veen S, et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16:2152-7
149. Barbir M, Rose M, Kushwaha S, et al. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. Int J Cardiol 1991;33:241-6
150. Vanhaecke J, Van Cleemput J, Van Lierde J, et al. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994;58:42-5
151. Pflugfelder PW, Huff M, Oskalns R, et al. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995;14:613-22
152. Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19:529-37
153. Weis M, Pehlivanli S, Meiser BM, et al. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001;38:814-18
154. Holschermann H, Hilgendorff A, Kemkes-Matthes B, et al. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 2000;69:1830-6
155. Smith JL, Roach PD, Wittenberg LN, et al. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 2000;15:871-9
156. Chapman BA, Burt MJ, Chisholm RJ, et al. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci 1998;43:349-53
157. Tazuma S, Kajiyama G, Mizuno T, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 1998;26:287-91
158. Maeda T, Matsunuma A, Kawane T, et al. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Comm 2001;280:874-7
159. Chan MH, Mak TW, Chiu RW, et al. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab 2001;86:4556-9
160. Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10
161. Van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001;285:1850-5.
162. Jick H, Zomberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000;356:1627-31
163. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43
164. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-61
165. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2001;4:CD003160
166. Boccuzzi SJ, Bocanegra TS, Walker JF, et al. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991;68:1127-31
167. Findlay Walker J. Worldwide experience with simvastatin/lovastatin. Eur Heart J 1992;13 (suppl B):21-2
168. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156:2085-92
169. Marz W, Wollschlager H, Klein G, et al. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). Am J Cardiol 1999;84:7-13
170. Ose L, Davidson MH, Stein EA, et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol 2000;23:39-46
171. Farmer JA. Learning from the cerivastatin experience. Lancet 2001;358:1383-4
172. Van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, et al. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996;240:403-4
173. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 1997;90:546-7
174. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural anti-oxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-4
175. Gruer PJK, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999;84:811-15
176. Kanathur N, Mathai MG, Byrd RP Jr, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001;94:339-41
177. Mogyorosi A, Bradley B, Showalter A, et al. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999;246:599-602
178. Al-Jubouri MA, Briston PG, Sinclair D, et al. Myxoedema revealed by simvastatin induced myopathy. Br Med J 1994;308:588
179. Lang JE, Wang P, Glueck CJ. Myopathy associated with lipid
180. Harris ML, Bron AJ, Brown NA, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol 1995;79:996-1002
181. Schmidt J, Schmitt C, Hockwin O. No lens changes caused by simvastatin: results from a prospective drug safety study. Lens Eye Toxic Res 1990;7:643-50
182. Schlienger RG, Haefeli WE, Jick H, et al. Risk of cataract in patients treated with statins. Arch Intern Med 2001;161:2021-6
183. Phan T, McLeod JG, Pollard JD, et al. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995;58:625-8
184. Ahmad A, Fletcher MT, Roy TM. Simvastatin-induced lupus-like syndrome. Tenn Med 2000;93:21-2
185. Andersen V, Sonne J, Andersen M. Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. Eur J Clin Pharmacol 2001;57:517-21
186. Blais L, Desgagne A, LeLorier J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000;160:2363-8
187. Manson JM, Freyssinges C, Ducrocq MB, et al. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996;10:439-46
188. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation 1984;69:313-24
189. Buchwald H, Varco RL, Matts JP, et al and the POSCH group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990;323:946-55
190. Buchwald H, Matts JP, Fitch LL, et al for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992;268:1429-33
191. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98
192. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-76
193. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8
194. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997;131:1-5
195. Bestehorn H-P, Rensing UFE, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease. The Multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34
196. Thompson GR, Maher VMG, Matthews S, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-16
197. Sutherland WHF, Restieaux NJ, Nye ER, et al. IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy. Arterioscler Thromb Vasc Biol 1998;18:577-83
198. Tayami R, Mabuchi H, Ueda K, et al. Intermediate density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 1981;64:1174-84
199. Krauss RM, Lindgren FT, Williams PT, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987;2:62-6
200. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial. Circulation 2000;102:1748-54
201. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, anti-oxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
202. Cheung MC, Zhao XQ, Chait A, et al. Anti-oxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001;21:1320-6
203. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997;96:1370-3
204. Walter DH, Schachinger V, Elsner M, et al. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000;85:962-8
205. Smilde TJ, van Wissen S, Wollersheim MH, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81
206. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001;104:249-52
207. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
208. Thompson GR. The proving of the lipid hypothesis. Curr Opin Lipidol 1999;10:201-5
209. Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol 1993;71:393-400
210. Crouse JR III, Byington RP, Hoen HM, et al. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305-10
211. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-5
212. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-5
213. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60
214. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-18
215. Pyorala K, Pedersen TR, Kjekshus J, et al and the Scandinavian Simvastatin Survival Study Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diab Care 1997;20:614-20
216. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7
217. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51
218. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 2000;86:257-62
219. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of anti-oxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-41
220. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
221. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23-32
222. Martens LL, Rutten FF, Erkelens DW. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands. Am J Cardiol 1990;65:27F-32F
223. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. Br Med J 1996;312:1443-8
224. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332-6
225. Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999;42:1293-301
226. Grover SA, Coupal L, Paquet S, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600
227. Krobot KJ, Wenke K, Reichart B. Simvastatin after orthotopic heart transplantation. Costs and consequences. Pharmacoeconomics 1999;15:279-89
228. Smith DG, Leslie SJ, Szues TD, et al. Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. Clin Pharmacoeconomics 1999;17:185-93
229. Miettinen TA, Gylling H, Strandberg T, et al for the Finnish 4S Investigators. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. Br Med J 1998;316:1127-30
230. Lee M-H, Lu K, Patel SB. Genetic basis of sitosterolemia. Curr Opin Lipidol 2001;12:141-9
231. Berger GMB, Pegoraro RJ, Patel SB, et al. HMG-CoA reductase is not the site of the primary defect in phytosterolemia. J Lipid Res 1998;39:1046-54
232. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30
233. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 1997;96:4226-31
234. Vuorio AF, Gylling H, Turtola H, et al. Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolaemia caused by the FH-North Karelia mutation. Arterioscler Thromb Vasc Biol 2000;20:500-6
235. Blair SN, Capuzzi DM, Gottlieb SO, et al. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000;86:46-52
236. Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Atherosclerosis 2000;151:135
237. Yeo WW, Yeo KR. Workload implications and cost of statin treatment in the National Service Framework for Coronary Heart disease. Br J Cardiol 2000;7 (suppl 4):511-18
238. Rodwell VW, Nordstrom JL, Mitschelen JJ. Regulation of HMG CoA-reductase. In Paoletti R, Kritchevsky D, eds. Advances in Lipid Research, vol. 14. New York: Academic Press, 1976:1-74